Bavarian Nordic’s $380 Million Acquisition of Emergent BioSolutions’ Travel Vaccines Portfolio

Walder Wyss AG acted as Swiss counsel to Bavarian Nordic.Bavarian Nordic, a vaccine company, has entered into a definitive agreement to acquire Emergent BioSolutions’ travel vaccines…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Federica Tiefenthaler

Author: Federica Tiefenthaler

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here